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Abstract
Background: Asthma is a phenotypically diverse disease with genetic susceptibility. A single nucleotide
polymorphism (SNP) in the CD14 gene at position -260 (also known as -159) C>T has been inconsistently
associated with asthma. The aim of this study was to estimate the combined likelihood of developing asthma
given the CD14 -260C>T genotype.
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,
a systematic search and meta-analysis of the literature was conducted to estimate the association between this
SNP and asthma. Planned subgroup analyses were performed to detect potential sources of heterogeneity from
selected study characteristics. Post-hoc sensitivity analysis was performed to identify studies exerting excessive
influence on among-study heterogeneity and combined effects.
Results: Meta-analysis of 23 studies yielded a non-significant overall association with high heterogeneity across
studies. After restricting analysis to studies using atopic asthma and non-atopic non-asthma case-control
phenotypes and excluding studies influencing heterogeneity, the genotype-specific odds ratios (ORs) suggested a
codominant model. Carriers of the TT and CT genotypes were about 33% less likely (OR = 0.67, 95% CI: 0.54-0.84)
and about 20% less likely (OR = 0.80, 95% CI: 0.66-0.95), respectively, to have atopic asthma compared to carriers of
the CC genotype. Among-study heterogeneity may be explained by overly broad asthma phenotype definitions,
gene-environment interactions, and gene-gene interactions.
Conclusions: A protective dose-response relationship between the CD14 -260T allele and atopic asthma
susceptibility was observed. These results demonstrate the importance of precisely specified case-control groups as
well as the need to assess interactions in the investigation of complex diseases such as asthma.
Background
Asthma is a common, complex, chronic medical condi-
tion characterized by lung inflammation, reversible air-
flow obstruction, and enhanced airway responsiveness to
a variety of environmental stimuli. Epidemiological evi-
dence suggests increased asthma prevalence in recent
decades with reduced international differences in asthma
prevalence [1]. The most common asthma phenotype is
atopic asthma, accounting for 56% of asthma cases in
the United States [2]. Atopic asthma is an immunoglo-
bulin E mediated hypersensitivity reaction triggered by
environmental allergens, such as endotoxin and aero-
allergens [3]. Although environmental factors are impor-
tant determinants of asthma, numerous studies have
revealed that asthma has a strong genetic component.
Susceptibility genes have been identified from linkage,
candidate gene association, and genome-wide associa-
tion studies. As of 2010, over 250 different genes have
been associated with asthma, including cluster of differ-
entiation 14 (CD14) [4,5].
A well studied common single nucleotide polymorph-
ism (SNP) in the promoter region of CD14, -260C>T
(rs2569190; also reported as CD14 -159), is the focus of
this review. CD14 encodes a receptor protein that binds
to lipopolysaccharide (LPS), its primary ligand, and
interacts with co-receptors toll-like receptor 4 (TLR4)
and lymphocyte antigen 96 (LY96). CD14 is expressed
on the surface of monocytes, macrophages, and neutro-
phils as membrane CD14 and in the serum as soluble
CD14 and its expression may be partially regulated at
the genetic level [6]. LPS, a principle component of
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from the outer membrane of Gram-negative bacteria.
Ligand binding activates innate immune system path-
ways that may trigger atopic asthma [7]. Atopic asth-
matic subjects are more sensitive to respirable
endotoxin than non-asthmatic subjects [8] and also
show increased expression of CD14 after acute allergen
provocation [9] and LPS inhalation [10].
Two earlier meta-analyses found an overall null asso-
ciation between the CD14 -260C>T polymorphism and
asthma, where no association was reported in some stu-
dies and the risk variant identified as either the T or C
allele in others [11,12]. Unfortunately, these meta-ana-
lyses lacked adequate reporting of methodology and
included studies examining non-asthma phenotypes. A
more recent meta-analysis found a significant decreased
atopic asthma risk for the TT and CT genotypes com-
pared with the CC genotype when analysis was
restricted to studies of Asian populations and children
[13]. However, that review had several significant errors
regarding study inclusion, data abstraction, and analyses.
Due to the inconsistency of past meta-analyses, an
updated review was conducted to estimate the meta-
odds of developing asthma given the -260C>T genotype
in CD14. Subgroup analyses were planned in order to
explore potential sources of among-study heterogeneity
by examining the effect of selected study characteristics
on the combined effect estimate. Methodological issues
in the literature studying this association are discussed.
Methods
Identification of eligible studies
Complete details of study methods are in Additional file
1. The review process followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [14]. A PubMed, EMBASE, and
Scopus search was conducted on April 29, 2011 using a
sensitive strategy to identify relevant articles. The HuGE
Literature Finder database was consulted for its listing
of articles under the asthma phenotype and CD14.A n
article in press at time of search was added to the
review [4]. Reference lists of articles retained for review
and past meta-analyses were inspected for relevant pub-
lications. No publication date or language restrictions
were imposed.
Article titles and abstracts of studies identified from
the searches were screened and excluded from further
analysis for the following reasons: ineligible phenotype,
ineligible SNP, review article, basic science research, or
animal research. The full-text of studies passing initial
screening was reviewed and excluded based on the
aforementioned and following criteria: not case-control
or nested case-control study design, unreported geno-
type frequencies, or subjects included in another study.
Studies must have an asthma outcome definition that
followed accepted diagnostic guidelines, was physician
diagnosed, or used a combination of questionnaire and
clinical ascertainment.
For multiple publications based on related data sets,
the study with the greatest number of subjects was
included. Reviewers extracted study information inde-
pendently and disagreements were resolved by discus-
sion and consensus.
Statistical analysis
The general approach to meta-analysis has been
described previously [15,16]. The pooled frequency of
t h ep u t a t i v er i s ka l l e l e( -260T) was estimated in various
ethnic groups using the inverse variance method. Het-
erogeneity of studies was assessed using the I
2 statistic
[17] separately for the genotype-specific odds ratios
(ORs) across studies: TT versus CC (OR1), CT versus
CC (OR2), and TT versus CT (OR3). If no or low het-
erogeneity existed (I
2 < 25%), the inverse variance
method was used to estimate the pooled OR and 95%
confidence interval (CI), assuming a fixed effects model.
Otherwise, a random effects model was used. Compari-
sons of OR1,O R 2,a n dO R 3 indicated the most appro-
priate genetic model for the -260T allele [16].
Subgroup analyses were planned when sufficient infor-
mation was reported in at least four studies in each sub-
group. The effect of having more homogeneous case
and control phenotype definitions (atopic asthma versus
non-atopic non-asthma), ethnicity, age, publication year,
or study size on the association was examined to iden-
tify potential sources of heterogeneity. Post-hoc sensitiv-
ity analysis using the sequential algorithm [18] with an
I
2 threshold of 25% was conducted in the presence of
significant among-study heterogeneity to evaluate stu-
dies responsible for the heterogeneity. Influence analysis
was conducted to allow identification of studies exces-
sively perturbing the summary estimate. Publication bias
was assessed visually using a funnel plot of the standard
error of the logarithm of the effect estimate against the
effect estimate of each study.
Review Manager Version 5.1.1 (Nordic Cochrane Cen-
tre, Cochrane Collaboration, Copenhagen, Sweden) was
used to conduct the meta-analysis, sequential analysis,
and publication bias assessment. MetaAnalyst Version
Beta 3.13 (Tufts Medical Center, Boston, MA) was used
to estimate the pooled -260T allele frequency and con-
duct the influence analysis.
Results
Study inclusion and characteristics
The literature search identified 204 potentially relevant
articles. Initial screening of titles and abstracts excluded
159 studies which did not meet the eligibility criteria.
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for review: 22 additional studies were excluded. Unpub-
lished CD14 -260C>T SNP data was provided by the
corresponding author for one study [4]. Multiple publi-
cations were discovered for two data sets [19-23]. The
studies with the largest number of subjects were
retained [20,23]. Since Chan et al. [20] did not include
g e n o t y p ef r e q u e n c yd a t ao na t o p i ca s t h m ac a s e sa n d
corresponding controls, this information was abstracted
from the related paper with shared subjects by Leung et
a l .[ 2 1 ] .I nt o t a l ,t h i sr e v i e wy i e l d e d2 3s t u d i e s
[4,11,20,23-42] for meta-analysis. Two studies were pub-
lished in Chinese [25,26] and one in Polish [32]. The
search results revealed that it was necessary to search
more than one database in order to capture all relevant
studies. Figure 1 provides a summary of the search
results.
All studies retained for review used either a case-con-
trol or nested case-control design. Of the 23 studies, 15
included mixed asthma cases [11,20,23,25,29,30,
33-40,42], of which five separated asthma cases by ato-
pic status [11,20,36,37,42], and eight included only ato-
pic asthma cases [4,24,26-28,31,32,41]. Thirteen studies
investigated European populations [4,11,24,27-36], eight
investigated East Asian populations [20,23,25,26,37-40],
and two investigated other populations [41,42]. Appro-
priate diagnostic criteria and proper genotyping meth-
ods were used in all studies. Eight studies applied some
form of genotyping quality control and only two
reported that genotyping was blinded to case-control
status. Deviation from Hardy-Weinberg equilibrium
(HWE) was detected in the controls of three studies
[27,33,42]. Genotype frequencies for the studies by
Bjornvold et al. [24] and Hakonarson et al. [28] could
not be ascertained and were estimated based on
reported allele frequencies, assuming HWE. All studies
used unique samples: a total of 4780 genotyped asthma
cases and 5650 genotyped non-asthmatic controls were
included in the meta-analysis. Study characteristics and
genotype frequencies are summarized in Table 1 (see
Table S1, Additional file 2, for a complete summary of
abstracted study characteristics).
Pooled CD14 -260T allele frequency in controls
Pooled CD14 -260T allele frequencies, using the inverse
variance fixed effects model, were 0.457 (95% CI: 0.445-
0.469) for overall European populations and 0.462 (95%
CI: 0.449-0.475) for European populations excluding
those not in HWE [27,33]. The pooled frequency was
0.577 (95% CI: 0.562-0.592) for East Asian populations.
The -260T allele frequency was 0.621 (95% CI: 0.576-
0.665) in an Indian population.
T and asthma risk",1,0,1,0,0pc,0pc,0pc,0pc>Association
between CD14 -260C>T and asthma risk
The pooled ORs for each pair-wise genotype compari-
son and corresponding I
2 statistics are summarized in
Table 2. For all studies, heterogeneity ranged from
Figure 1 Flow diagram of the systematic review and meta-analysis literature search results. HuGE is the Human Genome Epidemiology
Network.
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fic ORs, suggesting no association between the poly-
morphism and asthma risk. Subgroup analyses (data not
shown) did not show significant gene effects when stu-
dies were subset by ethnicity (European or East Asian),
age range of cases and controls (adults or children), year
of study publication (2006-2010 or 2001-2005), and gen-
otyped study sample size (≥ 100 cases and ≥ 100 con-
trols or < 100 cases or < 100 controls). Low to
moderate among-study heterogeneity was present in all
subgroups for OR2 and moderate to high heterogeneity
for OR1 and OR3. Sensitivity analysis excluding studies
that appeared to account for appreciable heterogeneity
and influence did not meaningfully change the results
for overall and subgroup meta-analyses (data not
shown). Relatively symmetrical funnel plots indicated
the absence of publication bias for the genotype-specific
ORs (see Figures S1-S3, Additional files 3, 4 and 5).
Subgroup analysis by case-control phenotype definitions
Initial subgroup analysis of studies that had defined
case-control phenotypes as atopic asthma and non-
Table 1 Characteristics and genotype distributions of reviewed studies on CD14 -260 (-159) C>T and asthma
Study Country Study design Outcome Cases Controls
Genotypes Genotypes
N CC CT TT N CC CT TT HWE p
European
Bjornvold [24]
a Norway CC AA 103 39 49 15 479 161 233 85 -
de Faria [27] Brazil CC AA 88 27 41 20 202 63 131 8 < 0.01
Hakonarson [28]
a Iceland CC AA 94 31 46 17 94 29 46 19 -
Heinzmann [29] Germany CC MA 182 51 89 42 261 79 124 58 0.48
Kedda [11]
b, c Australia CC AA, NAA 568 148 284 136 443 124 226 93 0.59
Koppelman [30] Netherlands CC MA 159 51 76 32 158 31 85 42 0.31
Kowal [31] Poland CC AA 372 141 152 79 160 42 73 45 0.27
Lis [32] Poland CC AA 50 20 24 6 73 28 34 11 0.90
Murk [4] USA CC AA 97 31 55 11 473 137 236 100 0.93
Sengler [33] Germany NCC MA 84 23 43 18 119 26 72 21 0.02
Smit [34] Denmark NCC MA 100 34 47 19 88 26 47 15 0.42
Smit [35] France CC MA 223 49 107 67 554 145 276 133 0.94
Woo [36]
b USA CC AA, NAA 175 46 94 35 61 20 35 6 0.10
Subtotal 2295 691 1107 497 3165 911 1618 636
East Asian
Chan [20]
d Hong Kong CC MA 269 55 134 80 141 26 77 38 0.23
Chen [25] China CC MA 150 63 62 25 150 40 68 42 0.25
Cui [26] China CC AA 143 27 67 49 72 10 42 20 0.11
Hong [37]
b South Korea CC AA, NAA 626 113 284 229 153 22 71 60 0.89
Kuo Chou [38] Taiwan CC MA 116 17 64 35 232 45 118 69 0.67
Park [39] South Korea CC MA 85 16 39 30 550 90 267 193 0.88
Wang [23] Taiwan CC MA 447 57 230 160 509 96 236 177 0.27
Wu [40] China CC MA 252 54 117 81 227 31 121 75 0.10
Subtotal 2088 402 997 689 2034 360 1000 674
Indian
Sharma [41] India CC AA 187 43 92 52 227 30 112 85 0.47
North African
Lachheb [42]
b Tunisia CC AA, NAA 210 46 90 74 224 36 72 116 < 0.01
Total 4780 1182 2286 1312 5650 1337 2802 1511
The number of successfully genotyped cases and controls may be less than the total number of cases and controls in the study (i.e. SNP call rate < 100%).
Genotype frequencies presented as reported, otherwise calculated from reported genotype percent frequencies. Abbreviations: AA, atopic asthma; CC, case-
control; HWE, Hardy-Weinberg equilibrium; MA, mixed asthma; N, genotyped sample size; NA, non-asthma; NAA, non-atopic asthma; NANA, non-atopic non-
asthma; NCC, nested case-control.
a Genotype frequencies estimated based on allele frequencies assuming HWE among cases and controls.
b Genotype distribution for AA cases shown (genotype distribution for NAA cases not shown).
c Genotype distribution for NA controls shown (genotype distribution for NANA controls not shown).
d Genotype frequency information from this data set for atopic asthma cases and corresponding controls (not shown) abstracted from Leung et al. [21].
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plus high among-study heterogeneity (Table 2). Further
subgrouping of studies comparing atopic asthmatics and
non-atopic non-asthmatics by ethnicity (European only),
age (children only), year of study publication, and geno-
typed study sample size did not meaningfully change the
results. Post-hoc sensitivity analysis identified three stu-
dies that may be responsible for the significant among-
study heterogeneity: Kedda et al. [11], de Faria et al.
[27], and Lachheb et al. [42]. While reported study char-
acteristics for these three studies were not atypical com-
pared to other studies, the controls for the studies by de
Faria et al. and Lachheb et al. deviated significantly from
HWE (p < 0.01). Influence analysis found moderate
influence on the combined effects exerted by these three
studies.
The genotype-specific ORs for the subgroup of studies
with atopic asthma versus non-atopic non-asthma case-
control groups, excluding the three studies identified by
the post-hoc sequential analysis, implied a codominant
model (Table 2). Compared to subjects with the CC
genotype, the pooled ORs suggested that subjects with
t h eT Tg e n o t y p ew e r es o m e3 3 %l e s sl i k e l yt oh a v ea t o -
pic asthma (OR1 = 0.67, 95% CI: 0.54-0.84, I
2 = 10%)
(Figure 2) and subjects with the CT genotype were
about 20% less likely to have atopic asthma (OR2 = 0.80,
95% CI: 0.66-0.95, I
2 = 0%) (Figure 3), showing a dose-
response relationship for the T allele. No substantial
heterogeneity was detected and publication bias was not
evident in the funnel plots (see Figures S4 and S5, Addi-
tional files 6 and 7). Exclusion of any one particular
study in the influence analysis did not meaningfully
change the results (data not shown).
Discussion
The present meta-analysis found a non-significant asso-
ciation between the CD14 -260C>T polymorphism and
overall asthma. There was also high among-study het-
erogeneity in the meta-analysis, possibly accounting for
the inconsistently reported findings between this SNP
and asthma [43]. Subgroup analysis of selected study
characteristics did not reveal any significant associations
or substantial decreases in the I
2 estimate of heterogene-
ity. When restricting analysis to studies that used atopic
asthma versus non-atopic non-asthma case-control phe-
notypes and excluding studies influencing heterogeneity,
the genotype-specific ORs suggested a codominant
model.
A sequential analysis revealed three studies that
appeared to account for the high among-study heteroge-
neity (see Additional file 1 for methodology). Two had
controls that departed from HWE, which may represent
possible sources of bias. The exploratory nature of post-
hoc sequential analysis may present a weakness, but
Table 2 Estimated ORs for CD14 -260 (-159) C>T and asthma
No. of
studies
ORs (95% CI) I
2 (%)
a Suggested genetic
model
TT vs. CC
(OR1)
CT vs. CC
(OR2)
TT vs. CT
(OR3)
OR1 OR2 OR3
Overall 23 0.88 (0.70-1.10) 0.87 (0.76-1.00) 1.01 (0.86-1.19) 68 36 56 NS
AA cases and NANA controls 13 0.89 (0.63-1.25) 0.90 (0.77-1.05) 1.01 (0.75-1.35) 69 23 69 NS
10
b 0.67 (0.54-0.84) 0.80 (0.66-0.95) 0.90 (0.75-1.08) 10 0 10 Codominant
European 8 1.11 (0.63-1.93) 0.97 (0.76-1.22) 1.14 (0.70-1.86) 79 36 75 NS
Children 8 0.92 (0.59-1.42) 0.89 (0.73-1.10) 1.05 (0.64-1.70) 64 0 80 NS
Year of publication
2006-2010
c 7 0.86 (0.53-1.37) 0.84 (0.69-1.03) 0.98 (0.61-1.59) 73 0 81 NS
2001-2005 6 0.95 (0.56-1.61) 0.91 (0.65-1.28) 1.03 (0.81-1.31) 66 47 15 NS
No. of cases and controls
d
≥ 100 cases and ≥ 100
controls
6 0.73 (0.48-1.10) 0.88 (0.64-1.23) 0.83 (0.69-1.00) 70 64 22 NS
< 100 cases or < 100
controls
7 1.15 (0.63-2.07) 0.88 (0.70-1.12) 1.34 (0.72-2.49) 69 0 78 NS
NAA cases and NANA controls 5 0.88 (0.39-1.97) 1.02 (0.67-1.57) 0.83 (0.54-1.27) 78 38 43 NS
Abbreviations: AA, atopic asthma; NAA, non-atopic asthma; NANA, non-atopic non-asthma; NS, non-significant; OR, odds ratio.
a Guideline for interpretation of the I
2 statistic: I
2 = 0% no heterogeneity, I
2 = 25% low heterogeneity, I
2 = 50% moderate heterogeneity, and I
2 = 75% high
heterogeneity [17].
b Excluding studies with excessive contribution to among-study heterogeneity identified by post-hoc sequential analysis [11,27,42].
c Including the in press article at time of search by Murk et al. [4].
d Numbers include only genotyped cases and controls.
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that specific study characteristics that may contribute to
heterogeneity are not always known or recorded. The
latter is important: if various methodological nuances
are not reported, subsequent meta-analysis would not
account for these factors and the ability to assess
sources of heterogeneity would be hampered. For
example, reported study characteristics in the article by
Kedda et al. [11], one of the studies identified to incur a
large amount of heterogeneity, did not reveal any parti-
cular characteristic that deviated from other studies.
Stronger associations and significant relationships
were found when analysis was restricted to studies with
more homogeneously defined case-control phenotypes
Figure 2 Forest plot of CD14 -260 (-159) TT versus CC genotypes for studies with precisely defined phenotypes. The forest plot displays
the meta-analysis results of studies included in the review that used atopic asthma versus non-atopic non-asthma case-control phenotypes,
excluding heterogeneous studies identified by sequential analysis [11,27,42]. Meta-analysis was conducted using an inverse variance (IV), fixed
effects model. For each study in the forest plot, the area of the black square is proportional to study weight and the horizontal bar represents
the 95% confidence interval (CI). Atopic asthma and non-atopic non-asthma are abbreviated as AA and NANA, respectively.
Figure 3 Forest plot of CD14 -260 (-159) CT versus CC genotypes for studies with precisely defined phenotypes. The forest plot displays
the meta-analysis results of studies included in the review that used atopic asthma versus non-atopic non-asthma case-control phenotypes,
excluding heterogeneous studies identified by sequential analysis [11,27,42]. Meta-analysis was conducted using an inverse variance (IV), fixed
effects model. For each study in the forest plot, the area of the black square is proportional to study weight and the horizontal bar represents
the 95% confidence interval (CI). Atopic asthma and non-atopic non-asthma are abbreviated as AA and NANA, respectively.
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indicated that the -260T allele was significantly protec-
tive under the codominant model when comparing ato-
pic asthmatics to non-atopic non-asthmatics. Observed
among-study heterogeneity may be partially explained
by the employment of overly broad case-control pheno-
type definitions. It has been suggested in genome-wide
association studies that use of homogeneous case phe-
notypes and precisely specified control groups—those
who unambiguously do not have the case phenotype—
m a yi m p r o v es t u d ye f f i c i e n c y[ 4 4 ] .T h i sp r i n c i p l e ,b o r -
rowed from extreme discordant sib-pair analysis [45],
naturally extends to case-control selection in candidate
gene association studies.
There is possible gene-environment interaction, in
which the SNP acts as a modifier of asthma risk in indi-
viduals with different degrees of environmental endo-
toxin exposure. Carriers of the TT genotype have been
found to have higher serum levels of CD14 than carriers
of the CT or CC genotypes [43]. This epidemiologic evi-
dence is supported by functional genomic studies that
showed increased transcriptional activity of the -260T
allele in a monocytic cell line [46]. An antagonistic
interaction has been demonstrated between CD14 and
endotoxin exposure: homozygotes for the T allele appear
to be protective for asthma at low levels of endotoxin
exposure, but may increase asthma risk at high levels of
endotoxin exposure [43]. Based on these findings, Marti-
nez [43] hypothesized that higher CD14 expression in
TT homozygotes increased sensitivity to the protective
effects of low level endotoxin exposure compared to car-
riers of other genotypes. However, at higher levels of
endotoxin exposure, induced CD14 expression could be
increased in carriers of the C allele, showing a reversed
protective effect. The findings of the present meta-ana-
lysis, restricted to studies using the atopic asthma versus
non-atopic non-asthma case-control phenotypes, are
consistent with this hypothesis at low endotoxin expo-
sure levels. The codominant model for the -260T allele
implied a dose-response relationship in CD14 expression
and reduction of atopic asthma risk. This gene-environ-
ment interaction may be a source of heterogeneity
among studies in the present and earlier meta-analyses
[11-13].
In addition to the promoter, many additional regula-
tory elements are necessary to influence gene expres-
sion, particularly for genes like CD14, which exhibit
highly complex expression patterns. Regulatory ele-
ments, such as enhancers and repressors, may reside in
intronic regions or up- and down-stream of the tran-
scriptional unit [47]. A risk variant with no obvious and
no known function may regulate a gene at a consider-
able genomic distance from the location of the SNP.
Therefore, it is important to study the influence of
gene-gene interaction as well as other polymorphisms in
CD14 on the effects of this locus on asthma
susceptibility.
Quality and methodology of studies
Assessing study quality was difficult due to inadequate
reporting from all studies included in the meta-analysis.
Many studies reported insufficient information about
recruitment methodology and study participant charac-
teristics, particularly for controls. Genotype distributions
of controls departed from HWE in three studies
[27,33,42]. Deviation from HWE in controls, or healthy
populations, may indicate selection bias, population stra-
tification, or genotyping errors [48]. Even in the absence
of deviation from HWE, these biases could not be
assessed given the inadequately reported information.
Eight studies reported implementing some form of gen-
otyping quality control [4,20,28,30,37,38,40,41]. Only
two published studies mentioned blinding of phenotype
when genotyping [29,38]. Furthermore, there is a poten-
tial for publication bias, where positive rather than nega-
tive findings tend to be published [49]. The
completeness of evidence is also impeded by language
bias. Studies conducted in non-English speaking coun-
tries tend to publish significant results in international
journals and non-significant results in local journals,
many of which are not indexed [50]. Selective publica-
tion of polymorphism and disease associations may
obscure their true relationships.
Results from the pooled CD14 -260T allele frequency
in controls revealed differences among the broad ethnic
categories: 0.457 for European populations, 0.577 for
East Asian populations, and 0.621 for an Indian popula-
tion. In comparison, the International HapMap Project
(Phase 3) reported the -260T allele frequency among
Utah residents with Northern and Western European
ancestry, Han Chinese in Beijing, China, Japanese in
Tokyo, Japan, and Yoruba inI b a d a n ,N i g e r i at ob e
0.474, 0.500, 0.488, and 0.293, respectively. The average
heterozygosity reported in Build 132 of dbSNP is 0.488
± 0.078 [51]. Interethnic differences in the allele fre-
quencies of the CD14 -260C>T polymorphism is of con-
cern as some studies included in this meta-analysis have
different ethnic compositions between the cases and
controls. Reported associations in studies of varying eth-
nic composition may have been influenced by popula-
tion stratification. Even among apparently homogeneous
ethnic groups, population stratification may be a pro-
blem [52]. The effect of this type of stratification has
been reported to be small in most situations, but a
small bias may be important in studies of genetic asso-
ciation, which typically consider small or moderate
effects [53]. Only four studies included in this review
reported an assessment of population stratification.
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stratification is the use of family-based designs to study
genetic associations [44,54]. However, the family-based
design has its own inherent limitation to susceptibility
variant discovery. It has been argued that neither com-
mon nor rare genetic variants are heritable, as they do
not give rise to a substantial familial concentration of
cases due to low penetrance [55]. Three family-based
studies have explored the association of CD14 -260C>T
and asthma with conflicting results [12,41,42]. There-
fore, efforts should be made to accrue controls from the
same source population as cases to avoid population
stratification, particularly when ethnicity is not matched
or controlled [44].
Conclusions
This meta-analysis provides a comprehensive examina-
tion of the available evidence concerning the association
between the CD14 -260C>T polymorphism and asthma
susceptibility. The significant association between this
polymorphism and atopic asthma may be of clinical and
public health importance. The genetics of asthma follow
the “common disease, common variants” hypothesis,
which posits that multiple genetic variants of interest
are common to many individuals with the disease.
These common variants typically have weak individual
effects and low penetrance, but their high frequency
confers a relatively large attributable risk in the popula-
tion. Therefore, this common polymorphism, along with
endotoxin exposure level information, has potential to
be a useful and efficient predictor of atopic asthma risk.
This review also emphasizes the importance of having
precisely defined case-control groups to study complex
diseases and demonstrates the need to incorporate
gene-environment and gene-gene interaction analyses in
future epidemiological investigations of asthma genetics.
Additional material
Additional file 1: Supplemental methods. Complete details of the
study methodology.
Additional file 2: Table S1. Summary of abstracted characteristics of
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